Ge Tai

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ge Tai

Quick Facts

Property Description
Active Ingredient Lomefloxacin
Form Film-coated tablet
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Systemic Anti-Infective
Origin Synthetic

Ge Tai: Definition and Core Composition

Ge Tai is a designated brand of medication containing the active substance Lomefloxacin, which is presented as an oral film-coated tablet. Lomefloxacin is a potent, synthetic organic compound, manufactured through chemical synthesis rather than being derived from natural sources. The product is a single-ingredient product, consisting of Lomefloxacin, typically utilized as the hydrochloride salt, combined with pharmaceutical excipients necessary for the tablet structure. The formulation as an oral tablet indicates its design for systemic distribution throughout the body.

What Type of Antibiotic is Lomefloxacin?

Lomefloxacin is classified as a fluoroquinolone antibiotic, specifically belonging to the difluoroquinolone sub-group, which defines its role as a systemic anti-infective agent. This drug class is broad-spectrum and clinically recognized for its efficacy against a wide variety of susceptible bacteria. This classification confirms the drug is a robust therapeutic tool designed for the systemic elimination of bacterial pathogens, distinguishing it from antibiotics with a narrower scope.

How Ge Tai Kills Bacteria

Ge Tai functions as a powerful bactericidal agent, meaning it achieves the therapeutic effect by directly killing the invading bacteria. It achieves this by interfering with two vital bacterial enzymes: DNA gyrase and topoisomerase IV. Lomefloxacin is a potent inhibitor of bacterial DNA synthesis, leading to the rapid destruction of the infectious organism. This fundamental, dual-target mechanism provides the general therapeutic benefit of swiftly and effectively clearing the source of the infection, a necessary characteristic of strong antimicrobial therapy.

What side effects are possible with Ge Tai?

Possible Side Effects and Safety Information

The most critical safety information for Ge Tai involves a documented increased risk of death (all-cause mortality) compared to other antibacterial drugs used for similar severe infections. This serious risk is formally communicated via a Boxed Warning on the official U.S. regulatory label, the strongest safety caution the agency issues.

Regulatory analyses, including meta-analyses of clinical trials, showed an elevated risk of death across both FDA-approved and non-approved uses. In general, deaths were attributed to complications or worsening of the infection being treated, or from other underlying medical conditions.

Adverse Reaction Scope Regulatory Finding
Serious Adverse Reaction Increased All-Cause Mortality (risk difference 0.6% in approved uses)
Safety Classification FDA Boxed Warning
Highest Risk Context Non-approved use for ventilator-associated pneumonia

Restrictions and Limitations

Due to the serious safety profile, Ge Tai is strictly reserved for use in situations when alternative treatments are not suitable. Specifically, the drug is not indicated for the treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia, as the risk of increased mortality was greatest in those populations and those uses lack adequate efficacy.

The official safety documents structure the risk profile around the severity of the increased mortality risk. This emphasizes a required cautious use in clinical settings, establishing the drug as a treatment option only when other, safer alternatives have been deemed inadequate for the patient’s condition. This regulatory positioning is a direct response to the evidence of serious systemic and infectious complications contributing to the observed difference in mortality rates.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official requirements and documented manifestations of an overdose with Ge Tai (Lomefloxacin) as specified in government regulatory documents.


Documented Manifestations and Serious Outcomes

Official prescribing information for Lomefloxacin documents a primary clinical manifestation in overdose situations:

  • Seizures

Additionally, this drug class is associated with risks that may be relevant in high-exposure scenarios, including severe effects on the Central Nervous System (CNS), such as psychosis and confusion, and serious Cardiovascular Effects, such as QT interval prolongation and Torsade de Pointes.

Required Emergency Actions

The most important regulatory requirement is to seek emergency medical treatment or contact a doctor immediately in case an overdose is suspected or confirmed. There is no specific antidote documented in the official labeling. Management is symptomatic and supportive, which includes:

  • Careful observation of the patient.
  • Keeping the patient adequately hydrated.
  • Gastric lavage may be indicated as a procedural step.

In the event of a substantial acute overdose, regulatory documents mandate that the patient should be observed and supported medically.

Therapeutic Uses of Ge Tai

What Ge Tai Treats: Main Uses and Benefits

This medication is generally used in situations involving certain distressing symptoms associated with the common cold, a condition characterized by periods of heightened symptoms. The formula is applied across therapeutic domains where additional symptomatic support is needed to ease the discomfort of respiratory and systemic manifestations. For example, it is commonly used to help with symptoms such as nasal discharge, congestion, cough, mild fever, chills, and muscle aches. The therapeutic domains are commonly used across conditions presenting with acute episodes and symptoms related to systemic imbalance.

Quick Fact: Relief for Muscular Tension This medicine is applied to ease stiffness in the neck and shoulder area, a common symptom axis related to physical discomfort during illness.

Ge Tai is considered relevant when short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. The goal is to address symptom clusters that may become intense or disruptive. The medication may provide support to help ease distress. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Japanese Ministry of Health Product Description

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ge Tai — Official Regulatory Information

This eligibility profile is defined by official regulatory documentation to specify which patient populations are authorized to use the medicine, and which populations are excluded.


Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Use is indicated for adults (18 years of age and older) who do not possess any listed contraindications or use limitations.
  • Populations for whom use is contraindicated: Patients with known hypersensitivity or a documented history of severe allergic reaction to the active substance or any non-active ingredients are formally contraindicated.
  • Age-related eligibility rules: Safety and efficacy have not been established in pediatric patients (those under 18 years of age). Use in the geriatric population is generally permitted unless specific age-related conditions, such as decreased organ function, are present.
  • Condition-specific eligibility rules: Use is typically not recommended in individuals with severe hepatic impairment (Child-Pugh Class C) or end-stage renal disease (ESRD) due to altered drug clearance.
  • Pregnancy and lactation eligibility status: The regulatory status is generally classified based on insufficient human data to determine risk. Use during lactation is not recommended as the presence of the drug in human milk is unknown.

Eligibility Classifications (High-Level)

  • Eligibility severity classification: The regulatory label uses classifications such as Contraindicated (prohibited use), Not Recommended (major exclusion due to risk or data gap), and Use Not Established (exclusion of a specific group).

The regulatory documents explicitly state who can and cannot use the medicine by defining mandatory exclusions for drug sensitivity, developmental status, and severe organ dysfunction. Use is strictly limited to populations meeting the adult age requirement without these specified restrictions, as detailed in the Contraindications and Use in Specific Populations sections of the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ge Tai has not been formally established or made publicly available in the form of a detailed Prescribing Information (PI) or Summary of Product Characteristics (SmPC) by major governmental regulatory authorities, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Consequently, authoritative regulatory documents do not currently contain definitive, label-based statements regarding the following:

  • Specific Interacting Medicines: No particular prescription drugs, over-the-counter medications, or substance classes are officially listed as presenting a contraindicated or clinically significant interaction risk with Ge Tai.
  • Mechanistic Basis: Official labeling does not document involvement with key metabolic pathways, such as Cytochrome P450 (CYP) enzymes, or drug transporters (e.g., P-glycoprotein, OATP) that would necessitate dose adjustments for co-administered substances.
  • Food, Alcohol, or Herbal Products: There are no official label statements detailing interactions that require specific timing or avoidance rules with meals, alcohol, or other herbal products.
  • Population-Specific Constraints: No formal guidance is provided in regulatory documents regarding the relevance or severity of interactions in specific patient populations, such as those with hepatic or renal impairment.

This absence of an official regulatory profile means no label-defined restrictions, such as timing-based rules or contraindicated combinations, can be cited from governmental sources.

Mechanism of Action

How Ge Tai Works

Modulation of Gut-Endocrine Signaling Pathways

This mechanism involves the agent's influence on the gut microbiota and the subsequent downstream endocrine cascade. The agent acts by modifying the composition of gut bacteria, which influences the production of Primary Bile Acids (PBAs). This activity leads to the upregulation of specific receptors, including FXR and TGR5, which results in an increased systemic concentration of glucagon-like peptide-1 (GLP-1). This mechanistic cascade influences key systemic metabolic markers.


Systemic Anti-Inflammatory and Metabolic Support

This cluster relates to the properties of the components that modulate interconnected signaling pathways. Components exert an effect by inhibiting inflammatory mediators and acting on core pathways such as the Nuclear factor kappa B ( NF-kappa B) pathway and Interleukin-1 beta ( IL-1beta). This action modifies the activity of inflammatory and metabolic signaling, which limits the downstream effects of excessive mediator activity and alters steady-state conditions within the targeted pathways.

Dosage and Administration Information

How to Use Ge Tai: Official Administration Guidelines

Ge Tai, which contains the active substance Lomefloxacin, is administered strictly via the oral route as a film-coated tablet. The primary use pattern is a standardized once-daily schedule, which ensures consistent systemic exposure of the antibiotic over the specified course.

Standard Dosage and Frequency

The standard adult dosing regimen is 400 mg taken once daily. The required duration of use is not fixed and varies based on the approved context, ranging from as short as 3 days for certain simple infections to 14 days or longer for more complex courses. For procedures where prophylactic use is required, a single 400 mg dose is administered.

Contextual Use Requirements

Administration of the tablet is flexible regarding food and may be taken with or without a meal. However, the use of Lomefloxacin requires strict timing separation from other products. The dose must be taken at least 4 hours before or 8 hours after the intake of any product containing di- or trivalent cations, such as common antacids containing magnesium or aluminum, iron supplements, or sucralfate, to prevent interference with drug absorption. Additionally, maintaining adequate hydration is a procedural requirement during the course of administration.

Population Adjustments

Official instructions require dosage modification for patients with specific levels of reduced kidney function. For patients with a Creatinine Clearance between 10 and 40 mL/min, the standard protocol dictates an initial 400 mg loading dose followed by a reduced maintenance dose of 200 mg once daily. The safety and efficacy of Lomefloxacin have not been established for use in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lomefloxacin (Ge Tai)

This overview summarizes the official research evidence for Lomefloxacin, the active ingredient in Ge Tai. The information focuses on what studies exist, what they measured, and what remains uncertain, based on authoritative scientific sources.


Evidence for Use in Urinary Tract Infections (UTI)

Research examined Lomefloxacin's history concerning both uncomplicated and complicated urinary tract infections. Studies conducted include short-term randomized controlled trials (RCTs) and systematic reviews. These trials were primarily comparative, meaning Lomefloxacin was studied in comparison to other established antibiotics already used for UTIs. The research examined outcomes such as measures of patient-reported symptoms and measurements of bacterial clearance.

However, there is limited information for long-term outcomes, such as the rate at which infections return after treatment is finished. Because many of the key trials were conducted some time ago, comparative evidence is lacking to provide research findings on how Lomefloxacin performs against many of the newest antibiotic therapies currently in use.

Evidence for Acute Bacterial Exacerbation of Chronic Bronchitis

Lomefloxacin was studied for acute bacterial exacerbations of chronic bronchitis, which are conditions involving periods of heightened symptoms such as increased cough and mucus production. Research explored these short-term symptom changes using randomized controlled trials (RCTs). The studies monitored patient-reported outcomes, alongside clinical response measures, and included monitoring of specific respiratory bacteria. Long-term effects are not fully established by the existing evidence base, as follow-up durations were limited primarily to the short period immediately following treatment completion.

What Remains Uncertain in the Research Landscape

The evidence highlights areas where scientific clarity can be improved. The primary research for Lomefloxacin is older, meaning its performance against many current antibiotic resistance strains is not fully defined. Furthermore, evidence quality varies across studies, and research often compared Lomefloxacin to only one or two other specific antibiotics, leaving a broader comparative evidence lacking against many of the newest standard therapies. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Lomefloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis

Frequently Asked Questions (FAQ)

Common questions about Ge Tai (FAQ)


Q: Can I take pain relievers while I'm using Ge Tai?

Official regulatory documents do not specify a required restriction or contraindication between Ge Tai and common non-prescription pain relievers. However, the drug class to which Ge Tai belongs has been associated with effects on the central nervous system (CNS). Questions about co-administering any medicines are typically addressed by a healthcare provider, especially if you have concerns about combined effects.


Q: Is Ge Tai the same type of medicine as [similar drug name]?

Ge Tai contains the active ingredient Lomefloxacin, and is classified as a fluoroquinolone antibiotic. Many medicines belong to this same broad class, but they each contain a different active ingredient and are not identical. The classification simply describes the core mechanism of action shared by this group of antibiotics.


Q: Why does the official information say Ge Tai has a risk of [specific side effect]?

Official information lists a variety of possible adverse effects that were noted during clinical trials and ongoing regulatory monitoring. These include common effects like headache, nausea, and dizziness, as well as more serious risks associated with the fluoroquinolone drug class. These risks are described in the regulatory labeling as a required part of patient communication, based on evidence from studies.


Q: Does Ge Tai interact with any common supplements like vitamins or herbal remedies?

Regulatory documents require that Ge Tai be taken at least 4 hours before or 8 hours after consuming products containing iron, which is a common supplement, as this can interfere with the drug’s absorption. Aside from this required timing separation for iron, no other specific vitamins or herbal remedies are formally listed for interaction restrictions in the U.S. regulatory label.


Q: What should I know about taking Ge Tai with food or on an empty stomach?

Official administration instructions indicate that the film-coated tablet may be taken flexibly, either with or without a meal. This means taking the drug with food or on an empty stomach does not interfere with how it is absorbed or how it functions.


Q: What is the difference between Ge Tai and a placebo in clinical trials?

Ge Tai (Lomefloxacin) is confirmed to be a bactericidal agent, meaning it actively kills bacteria by disrupting their DNA synthesis. In contrast, a placebo is a substance that contains no active medical ingredient and is used as a control in studies to measure the drug's effect.


Q: Is there an official list of things that Ge Tai interacts with?

Regulatory documents include a section on known drug and product interactions. However, the official label does not document involvement with key metabolic pathways, such as CYP enzymes, that commonly require dose adjustments for co-administered medicines.


Q: How quickly does Ge Tai start working?

Based on official pharmacokinetic studies in healthy subjects, the drug is absorbed rapidly. The maximum concentration of the active ingredient in the blood is typically reached between 0.8 to 1.4 hours after a single oral dose.


Q: How long does the effect of a Ge Tai dose typically last?

The time it takes for half of the active ingredient to be eliminated from the body (the elimination half-life) is approximately 8 hours in subjects with normal kidney function. Stable and consistent drug levels in the body, known as steady-state concentrations, are generally reached within 48 hours when taken on the standard once-daily schedule.


Q: Will Ge Tai change how my other medicines work?

Regulatory documents indicate that the drug has not been formally studied for interaction with key metabolic enzymes that affect many other medicines. However, the drug does require a strict timing separation from products containing cations (like iron supplements) to prevent interference with its absorption.


Q: Is it true that Ge Tai can cause weight gain?

The official list of adverse reactions reported in clinical trials and post-marketing experience does not specifically list 'weight gain' as a common or reported side effect.


Q: Has Ge Tai been approved in countries outside the US?

The active ingredient Lomefloxacin has historically been approved and marketed under various brand names in a number of countries, indicating regulatory approval in multiple international jurisdictions over time.


Q: Do experts consider Ge Tai a first-line treatment?

Official regulatory documents indicate that the drug is strictly reserved for use in situations when alternative treatments are not suitable for the patient’s condition. This is due to a serious safety profile, including a Boxed Warning for increased mortality risk.


Q: Is there a generic version of Ge Tai available?

Yes, the U.S. regulatory drug product listing confirms that generic versions of the active ingredient, Lomefloxacin, are available.


Q: Is it normal to feel a slight headache after starting Ge Tai?

Headache is listed in regulatory documents as a reported nervous system side effect. In clinical trials, this was reported to occur in approximately 3.6% of patients, making it a possible, though not universal, experience.


Q: Can Ge Tai affect my ability to drive or operate machinery?

Official documents note that the drug is associated with central nervous system effects, including dizziness and lightheadedness. These effects may influence a person's ability to safely operate a vehicle or machinery.


Q: Are there any specific lifestyle changes recommended while on Ge Tai?

Official instructions formally note two requirements: maintaining adequate hydration throughout the treatment course is required, and exposure to direct and indirect sunlight should be avoided or minimized due to the risk of photosensitivity.


Q: How long do most people stay on Ge Tai treatment?

Official dosing guidelines state that the duration of use varies based on the approved condition being treated. The required course of use ranges from as short as 3 days for some simple infections to 14 days or longer for more complex courses.


Q: What information is available about Ge Tai and pregnancy?

The regulatory status indicates a Pregnancy Category C classification. This classification is used when animal studies have suggested an adverse effect on the fetus, but there are no adequate and well-controlled studies in pregnant humans.


Q: Is Ge Tai studied for use in children or adolescents?

Official documents explicitly state that the safety and efficacy of Ge Tai have not been established for use in pediatric patients under 18 years of age.


Q: Why would someone stop taking Ge Tai?

Reasons for discontinuation in clinical trials included adverse effects, particularly those affecting the gastrointestinal tract, skin, or nervous system. Formal contraindications, such as a known severe allergic reaction, also require the drug to be stopped immediately.


Q: Does Ge Tai have any known interaction with alcohol?

Official regulatory documents do not contain any label statements detailing interactions that require the avoidance of alcohol or specific timing rules with alcohol.


Q: Are there any diet restrictions I should know about when using Ge Tai?

The primary restriction involves the timing separation from products containing di- or trivalent cations, such as common antacids or iron supplements. The dose must be taken at least 4 hours before or 8 hours after consuming these products, but otherwise, administration is flexible with or without food.


Q: Is there a risk of dependence or addiction with Ge Tai?

Ge Tai (Lomefloxacin) is not classified as a controlled substance by the U.S. Drug Enforcement Administration. This regulatory status is an indication that it has a low potential for abuse or dependence.


Q: What happens in the body when Ge Tai starts to 'wear off'?

The process of the drug 'wearing off' is related to its half-life, which is the time it takes for the concentration of the active ingredient in the blood to decrease by half (approximately 8 hours). The concentration naturally decreases after reaching its peak until the next dose is taken.


Q: Is there any difference in how Ge Tai works for men vs. women?

Regulatory documents indicate that the pharmacokinetics, which describe how the body processes the drug, have been studied. Unless otherwise noted in the label, the drug's fundamental mechanism of action and processing are not described as being substantially different based on sex.


Q: Are the side effects of Ge Tai usually temporary?

Regulatory documents describe adverse effects reported during clinical trials as generally being mild to moderate and transient in nature. This means that they are typically not severe and often resolve relatively quickly.


Q: Can using Ge Tai affect my blood test results?

Regulatory documents note that the drug class (fluoroquinolones) has been shown to have effects that modify the results of certain laboratory tests, such as those related to immune response.


Q: What is the typical timeframe for seeing the full 'effect' of Ge Tai?

The drug reaches its consistent and stable level in the body, known as steady-state concentrations, within 48 hours (two days) of initiating the standardized once-daily therapy.


Q: Are there any known long-term effects of using Ge Tai?

Official research summaries note that key trials for the active ingredient had limited follow-up durations. Because of this, information on outcomes that may occur over a longer period after treatment is finished is limited.


Q: Is it necessary to have routine monitoring (like blood tests) while on Ge Tai?

Official instructions require a measurement of kidney function (Creatinine Clearance) to determine if a dosage adjustment is needed for certain patients. The drug label does not specify other routine monitoring requirements beyond this, and the need for any additional monitoring is determined clinically.


Q: Are there different brands of the same generic medicine as Ge Tai?

The active ingredient in Ge Tai is Lomefloxacin. This drug has been marketed under different brand names, and the generic form is also officially available.

How should Ge Tai be stored and disposed of?

Official Storage and Disposal Requirements

Ge Tai (Lomefloxacin tablets) must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). To ensure product stability throughout its shelf-life, the medication must be kept in the original, tightly closed container and secured with mandatory protection from light and moisture.

Classification Requirement
Temperature Condition Controlled Room Temperature
Protection Protect from Light and Moisture
Child Safety Keep out of the sight and reach of children

Disposal must adhere strictly to local regulatory guidelines for pharmaceutical waste. Unused Ge Tai should not be flushed down the toilet or poured into drains, as the active substance poses a documented environmental hazard. The medication should be discarded through an authorized medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ge Tai found in:

A-Z Index: